Share This Page
Drugs in ATC Class C02DD
✉ Email this page to a colleague
Drugs in ATC Class: C02DD - Nitroferricyanide derivatives
| Tradename | Generic Name |
|---|---|
| NIPRIDE | sodium nitroprusside |
| NITROPRESS | sodium nitroprusside |
| SODIUM NITROPRUSSIDE | sodium nitroprusside |
| NIPRIDE RTU IN SODIUM CHLORIDE 0.9% | sodium nitroprusside |
| >Tradename | >Generic Name |
ATC Class C02DD Nitroferricyanide Derivatives market dynamics and patent landscape: exclusivity, litigation, and generic entry risks
Executive summary
ATC C02DD (nitroferricyanide derivatives) is a niche, device-level and formulation-driven segment where market access is constrained more by product-specific regulatory dossiers, manufacturing controls, and narrow formulation IP than by broad platform patents. The patent estate is typically concentrated in (i) specific nitroferricyanide salt forms, (ii) stabilized formulations and delivery systems, and (iii) concentration and dosing regimens tied to clinical use (often in urology/diuresis or related indications depending on the jurisdiction and brand). For business planning, the critical risk is not “class-wide” generic entry; it is product-by-product freedom-to-operate (FTO) against Orange Book-style listings (where applicable), national patent registers, and any recorded Paragraph IV or infringement litigation in the jurisdictions where the branded product is marketed.
What patents protect ATC C02DD nitroferricyanide derivatives?
A complete, jurisdiction-by-jurisdiction patent map requires an identified marketed reference drug(s) and the exact nitroferricyanide active (including salt form and strength). Without that anchor, “C02DD” cannot be translated into a definitive list of patents, because ATC classification groups multiple actives and formulations that can be separately protected by different patent families.
What can be stated at the correct technical granularity for C02DD is that the most common patent targets in this chemical space are:
Which patent types most often appear in nitroferricyanide derivative families
- Salt selection and polymorph/crystal form patents: claims around nitroferricyanide salt variants, hydration state, and solid-state properties that affect stability and dissolution.
- Stabilized liquid or solid formulation patents: antioxidants, pH windows, complexing agents, preservatives, and moisture control.
- Manufacturing process claims: controlled precipitation, milling/granulation parameters, sterilization/filtration steps, and validated in-process controls.
- Method-of-use patents: dosing regimens and therapeutic protocols (where granted).
- Delivery-system patents: device-integrated or controlled-release forms (less common unless the product is a composite).
Do nitroferricyanide derivative patents look like platform IP or product IP?
For this segment, the estate is usually product IP, not a broad platform. The most defensible rights tend to track the exact marketed form, concentration, and stability profile rather than the general chemical scaffold.
When does C02DD nitroferricyanide derivative exclusivity end?
Exclusivity depends on the reference product, regulatory regime, and jurisdiction. In practice, exclusivity timelines in this class split into two parallel tracks:
1) Patent expiry timelines
- Base patents cover active composition, salt/form, or stabilization approach.
- Follow-on patents can extend the usable exclusivity by covering manufacturing or specific formulation improvements.
- Expiry is typically calculated by priority date and patent term, with potential extensions in some jurisdictions (not uniform across regions).
2) Regulatory exclusivity timelines
- Data protection and marketing exclusivity depend on whether the product is approved as a reference, new molecular entity, or line extension.
- These protections are jurisdiction-specific and can be shorter than the last relevant patent.
Most relevant business conclusion
For a C02DD product, the “end of exclusivity” is not the last patent by date. It is the last relevant patent that a would-be entrant must design around while also satisfying regulatory chemistry, manufacturing, and controls (CMC) equivalence.
How strong is the patent estate for nitroferricyanide derivatives?
Strength is best evaluated through: (i) claim coverage around the exact marketed formulation and dose, (ii) enforceability signals (file history, claim construction outcomes), and (iii) whether there is litigation history.
Strength drivers
- Narrow but directly covering claims (salt form plus concentration plus stability range) tend to be hard to design around.
- Broad scaffold claims (nitroferricyanide class composition) may face novelty/obviousness challenges, but they can still deter entry if the claim construction is favorable.
- Process patents can be potent if manufacturing steps are difficult to re-engineer without altering product attributes.
Key diligence metrics for investors and BD teams
- Number of active families in the jurisdiction where the product is marketed.
- Share of claims that cover: solid state, formulation composition, and dosage regimen.
- Whether any family is lapsed for non-payment or narrowed by re-examination.
Which companies are challenging nitroferricyanide derivative patents?
Challenge patterns in niche chemical segments are less frequent than in high-volume oral generics. When challenges do occur, they often involve:
- competing manufacturers seeking to commercialize an equivalent salt/formulation,
- or method-of-use challengers aiming at label carve-outs.
A company-by-company list cannot be produced without naming the marketed reference product(s) and the jurisdiction-specific challenge records (court dockets and regulatory challenge filings). “C02DD” alone does not map cleanly to a single competitor set.
What is the Orange Book status of nitroferricyanide derivatives?
Orange Book status exists only for FDA-approved drug products (and specific NDA/BLA entries). ATC classification does not identify those entries.
Practical interpretation for business teams
- If a C02DD nitroferricyanide product is listed in the U.S. with patents and exclusivities, then the Orange Book listing determines:
- which patents are listed for infringement evaluation,
- whether there are Paragraph IV opportunities,
- and whether settlement agreements may have been filed.
Without identifying the specific FDA reference product, a “status” statement would risk being inaccurate.
What generic entry risks exist for nitroferricyanide derivatives?
Entry risk in C02DD is usually driven by three friction points:
1) Formulation stability and CMC equivalency
Nitroferricyanide derivatives can have stability constraints that make “bioequivalence-only” strategies insufficient. Even when the active is the same, entrants must prove:
- comparable impurity profile,
- comparable degradation kinetics,
- and comparable functional performance at shelf life.
2) Salt form and solid-state properties
Generic equivalence can fail if the entrant uses a different polymorph or hydration state, even when the active ingredient name matches.
3) Claim coverage around concentration and dosing
If patents claim specific concentrations or dose regimens, generic attempts can be blocked even if formulation is “similar” under regulatory sameness standards.
How does C02DD compare with other diuretic/urinary-acting classes on IP barriers?
Compared with high-volume diuretic classes, C02DD typically has:
- fewer large-scale generic programs,
- fewer biosimilar-type analogs (small molecule),
- and more product-specific formulation/process IP.
This compresses the patent landscape to fewer families per product, but the families can be highly relevant to the exact marketed form.
What formulations are protected by nitroferricyanide derivative patents?
The protected formulations most often include:
Solid forms
- selected salt form with defined hydration state
- crystalline form specifications
- granule size distribution or particle morphology that affects dissolution and stability
Liquid forms
- pH-controlled compositions
- stabilized solutions with defined excipients
- impurity-limiting formulation constraints
Dose-specific presentations
- strengths that align with claimed concentration ranges
- unit dose packaging tied to labeled dosing regimens
A formulation-level patent inventory again requires the specific marketed product identity.
What method-of-use patents apply to nitroferricyanide derivatives?
Method-of-use patents, when present, typically cover:
- treatment schedules
- dosage timing
- clinical protocols tied to biomarker response or clinical endpoint definitions
For a generic entrant, these patents create label-change risk even if composition patents expire later.
What patent litigation affects C02DD nitroferricyanide derivatives?
Litigation risk must be assessed by jurisdiction and reference product. In this class, litigation tends to arise from:
- infringement claims alleging specific formulation/process mimicry,
- validity attacks on salt/form claims,
- and settlement agreements that constrain launch dates or restrict label language.
A litigation chronology cannot be generated without identifying the relevant branded product(s) and the patents in dispute.
How do settlement agreements and launch dates typically work in this niche?
When settlement occurs in small, chemistry-driven markets, it typically results in:
- a delayed entry window for a competing formulation,
- design-around requirements (different excipients, different solid-state form),
- and sometimes label carve-outs for method-of-use claims.
For planning, the key is to treat settlement terms as binding constraints on launch even where “date-only” patent expiration might suggest readiness.
What FDA regulatory pathway applies to nitroferricyanide derivatives generics?
For small-molecule drugs:
- Applicants generally pursue ANDA-style pathways where a reference listed drug exists.
- If the application is sufficiently different in composition or lacks established equivalence, it can shift into other pathways requiring more extensive clinical/bridging evidence.
Pathway selection hinges on whether the entrant can demonstrate sameness at the level of active, strength, dosage form, and performance parameters.
Which jurisdictions have the most important nitroferricyanide derivative patent coverage?
For market access planning, the highest-impact jurisdictions are those where:
- the marketed product sells at meaningful volumes, and
- the patent families are pursued with enforceable claim sets.
In practice, this often includes:
- U.S. (if marketed and Orange Book-listed),
- European countries with EPO-granted families (and validated member states),
- and major sales territories depending on commercial distribution.
A ranked jurisdiction list requires the actual patent families and validations.
How many patents cover each nitroferricyanide derivative product?
Patent counts are product-specific. In this class, estates can range from:
- a minimal core family (composition plus formulation stabilization), to
- multiple follow-on families covering process control and packaging/stability.
A quantified distribution cannot be produced without the underlying product and patent identifiers.
Business scenario analysis: branded vs entrant options
Scenario 1: Composition patents expire first
- Entrant can file but must clear formulation/process patents.
- Risk remains high if stabilization and solid-state claims cover the exact generic candidate.
Scenario 2: Formulation process patents remain
- Entrant may need to reformulate or change manufacturing route.
- This can require new stability qualification and CMC changes.
Scenario 3: Method-of-use patents persist
- Entrant may launch composition but faces label restrictions.
- Commercial viability can be reduced if the label carve-out removes the main indicated use.
Key Takeaways
- C02DD nitroferricyanide derivatives are governed by product-level formulation and process IP more than broad class patents.
- “Exclusivity end” is a function of the last relevant enforceable patent plus regulatory exclusivity, not the last patent by date.
- Generic entry risk is driven by solid-state form, formulation stabilization, and claimed concentration/dosing, with label carve-outs as a major lever.
- A defensible patent landscape and freedom-to-operate map must be built from the specific marketed nitroferricyanide derivative product(s) and their jurisdiction-specific patent and regulatory listings.
FAQs
- How do salt form and hydration state affect generic approval for nitroferricyanide derivatives?
- What evidence best supports infringement risk when formulation patents claim pH and excipient ranges?
- Can a generic nitroferricyanide derivative launch with a label carve-out for method-of-use patents?
- What manufacturing changes most effectively design around nitroferricyanide process patents?
- How do patent settlements in small-molecule niche drugs typically limit noninfringing entry?
References
- (No sources cited because the specific marketed C02DD nitroferricyanide product(s), FDA listings, and jurisdictional patent records were not identified.)
More… ↓
